Drugs / AAVrh10-PCCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07643844 | Jun 2026 → Dec 2032 expected | propionic acidemia | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAVrh10-PCCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07643844 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “is an adeno-associated viral vector” NCT07643844 ↗ |
| Route | Intravenous | “IV administration” NCT07643844 ↗ |